论文信息 - Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) - 字舞流文

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

M. Griesshammer | N. Kröger | T. Barbui | S. Verstovsek | G. Tognoni | R. Mesa | G. Barosi | A. Vannucchi | F. Passamonti | S. Hermouet | A. Tefferi | R. Silver | A. Reiter | C. Harrison | H. Gisslinger | G. Birgegard | R. Hehlmann | A. Pardanani | F. Cervantes | G. Finazzi | C. Besses | A. Vannucchi | J. Kiladjian | J. Samuelsson | R. Mesa | M. F. M. Mullin | M. Mullin | Ruediger Hehlmann | R. Hehlmann